Breaking News

Aligning Management Group offered New Refined Industrial Concentrate on Institutions Beginning with Current Appointment of Board Member Zhenya Lindgardt as Interim President and CEO

Engages Top Approach Home to Evaluate Finest Pathways Toward Targeting Enhanced Income Generation at Considerably Decreased Operating Charges

Nadia Altomare Anticipated to Move from Chief Industrial Officer to Consulting Function to Assistance Driving Efficiency and Effectiveness in Our Industrial Devote in Partnership with Our External and Internal Group

SALT LAKE CITY, Could 25, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on enhancing maternal and neonatal wellness by giving revolutionary pregnancy biomarker facts to physicians and individuals, currently announced specific industrial alterations and plans to optimize its approach and industrial structure to hugely concentrate company activities on accelerating test adoption and income at substantially lowered operating expenses.

These plans include things like alterations to far better align leadership with a new refined industrial concentrate on institutions and price-successfully accelerating test adoption and income in advance of upcoming information readouts. This course of action began with the current appointment of Board Member Zhenya Lindgardt, a seasoned company operator for higher-development organizations, as interim President and CEO, announced on Could 15, 2023.  

Sera Prognostics has also engaged a major approach home to rigorously evaluate the greatest pathways toward enhanced income at substantially lowered price to a lot more broadly commercialize the company’s PreTRM® Test and pipeline of technologies. This evaluation is anticipated to be inclusive of effective market place concentrate and possible strategic partnerships. As element of this course of action, Nadia Altomare is anticipated to move from Chief Industrial Officer to a consulting function to assistance driving efficiency and effectiveness in our industrial devote in partnership with our external and internal group.

The Corporation has also produced pick headcount reductions at month finish in its industrial organization to far better map present industrial and marketing and advertising expenses toward refined concentrate on these possibilities becoming deemed as the most profitable in the close to-term from a test adoption and income generation point of view. Sera Prognostics is evaluating other approaches to additional optimize its company though decreasing operating expenses and guarding its powerful balance sheet, which presently affords a powerful foundation toward realization of the Company’s ambitions outlined currently coupled with targeting enhanced shareholder valuation.

“We are taking decisive and nicely-defined methods to optimize for market place good results offered the macro atmosphere, though also taking into consideration the emerging function we seek to play in establishing our initial-of-its-sort PreTRM test as a regular of care in guarding mothers and babies,” stated Sera Prognostics interim CEO, Zhenya Lindgardt. “When alter is at instances difficult, we anticipate our actions will prove profitable in supporting our target to be The Pregnancy Corporation though fostering important development, and we are thankful for our team’s function in producing a paradigm shift in pregnancy care to develop far better healthcare outcomes for expectant mothers and their youngsters.”

About Sera Prognostics, Inc.

Sera Prognostics is a major wellness diagnostics business committed to enhancing the lives of ladies and babies via precision pregnancy care. Sera’s mission is to offer early, pivotal pregnancy facts to increase the wellness of mothers and newborns, resulting in reductions in the expenses of healthcare delivery. Sera has a robust pipeline of revolutionary diagnostic tests focused on the early prediction of preterm birth danger and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a doctor the individualized danger of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in ladies with larger danger. Sera Prognostics is positioned in Salt Lake City, Utah.

About Preterm Birth

Preterm birth is defined as any birth prior to 37 weeks’ gestation and is the major bring about of illness and death in newborns. The 2022 March of Dimes Report Card shows that, for the final 4 consecutive years, a lot more than one particular in ten infants is born prematurely. Prematurity is linked with a substantially improved danger of main extended-term health-related complications, such as mastering disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can create important expenses all through the lives of impacted youngsters. The annual wellness care expenses to handle quick- and extended-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.

About the PreTRM® Test

The PreTRM® Test is the only broadly validated, commercially offered blood-primarily based biomarker test that delivers an early, correct and individualized danger prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are hugely predictive of preterm birth. The PreTRM® Test permits physicians to recognize, for the duration of the weeks 18 via 20 of pregnancy, which ladies are at improved danger for preterm birth and its complications, enabling a lot more informed, customized clinical choices primarily based on every woman’s person danger. The PreTRM® Test is ordered by a health-related qualified.

Sera Prognostics, the Sera Prognostics logo, The Pregnancy Corporation, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other nations.

Secure Harbor Statement

This press release includes “forward-seeking statements” inside the which means of the Private Securities Litigation Reform Act of 1995, such as statements relating to accelerating test adoption and income targeting enhanced income generation at substantially lowered operating expenses driving efficiency and effectiveness in our industrial devote upcoming information readouts possible strategic partnerships additional optimizing the Company’s company enhanced shareholder valuation establishing the Company’s initial-of-its-sort PreTRM test as a regular of care fostering important development and the company’s strategic directives below the caption “About Sera Prognostics, Inc.” These “forward-seeking statements” are primarily based on management’s present expectations of future events and are topic to a quantity of dangers and uncertainties that could bring about actual final results to differ materially and adversely from these set forth in or implied by forward-seeking statements. These dangers and uncertainties include things like, but are not restricted to: net losses, money generation, and the possible require to raise a lot more capital revenues from the PreTRM Test representing substantially all Corporation revenues to date the require for broad scientific and market place acceptance of the PreTRM Test a concentrated quantity of material prospects our potential to introduce new merchandise possible competitors our proprietary biobank crucial suppliers the COVID-19 pandemic and its possible lingering influence on our operations, as nicely as the company or operations of third parties with whom we conduct company estimates of total addressable market place chance and forecasts of market place development possible third-celebration payer coverage and reimbursement new reimbursement methodologies applicable to the PreTRM Test, such as new CPT codes and payment prices for these codes alterations in FDA regulation of laboratory-created tests the intellectual house rights guarding our tests and market place position and other aspects discussed below the heading “Threat Elements” contained in our Final Prospectus on Type S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as nicely as any updates to these danger aspects filed from time to time in our Quarterly Reports on Type ten-Q, Annual Reports on Type ten-K, or Existing Reports on Type eight-K. All facts in this press release is as of the date of the release, and the Corporation undertakes no duty to update this facts unless essential by law.

Supply Sera Prognostics, Inc.

Leave a Reply